• LAST PRICE
    11.9400
  • TODAY'S CHANGE (%)
    Trending Up0.1100 (0.9298%)
  • Bid / Lots
    11.7600/ 2
  • Ask / Lots
    12.0000/ 5
  • Open / Previous Close
    11.8100 / 11.8300
  • Day Range
    Low 11.7750
    High 12.0200
  • 52 Week Range
    Low 8.7400
    High 13.6175
  • Volume
    11,960,078
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Mar 27, 2024

      Show headlines and story abstract
    • 6:59AM ET on Wednesday Mar 27, 2024 by PR Newswire
      Companies Mentioned: VTRS

      At a meeting with the investment community today, Viatris Inc.(NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of building a more durable, higher-margin portfolio of patented innovation on the foundation of its strong base business. The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.

    • 6:59AM ET on Wednesday Mar 27, 2024 by Dow Jones
      Companies Mentioned: VTRS

      This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements regarding how it is continuing to evolve its R&D strategy to deliver on its goal of building a more durable, higher margin portfolio of patented innovation on the foundation of its strong base business; its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline; our confidence in our ability to continue to drive future growth and unlock shareholder value comes from our strong base business, well-established global infrastructure, and significant financial flexibility all of which give us the opportunity to continue to evolve our pipeline with the addition of potential blockbuster assets like selatogrel and cenerimod; the addition of high-science programs that deliver novel, meaningful patient impact and address significant unmet patient need will also give us the opportunity to accelerate long-term growth; the collaboration with Idorsia is a great example of Viatris' strategy in action--adding two late-stage potential blockbuster assets, selatogrel and cenerimod--and connecting Idorsia's highly productive drug development team and innovation engine with Viatris' existing infrastructure and experience; the Company's high-margin organic pipeline, which it expects will deliver $450 million to $550 million in revenue in 2024; information about selatogrel and cenerimod, information about clinical trials and studies; that a special protocol assessment has been agreed with the FDA, indicating its concurrence with the adequacy and acceptability of critical elements of overall protocol design for a study intended to support a future marketing application; selatogrel has received fast-track designation from the FDA; the investigation of cenerimod for the treatment of SLE has received fast-track designation from the FDA. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the outcome of clinical trials and studies; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; the possibility that Viatris may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that Viatris may be unable to achieve intended or expected benefits, goals, outlooks, synergies, growth opportunities and operating efficiencies in connection with divestitures, acquisitions, other transactions or restructuring programs, within the expected timeframes or at all; goodwill or impairment charges or other losses related to the divestiture or sale of businesses or assets; Viatris' failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.
  • Mar 11, 2024

Peers Headlines